RECIST disease assessment is effective for targeted treatment as well as classical chemotherapy
A multinational multi-tumour basket study in very rare cancer types: the European Organisation for Research and Treatment of Cancer phase II 90101 "CREATE" trial (2019)
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial (2019)
Cumulative toxicity in targeted therapies: what to expect at the recommended Phase II dose (2019)
The EORTC Cancer Research Fund aims to raise funds to support the independent academic cancer research activities of the EORTC.
The EORTC fellowship offers opportunities to learn the principles of cancer clinical research by being attached to a specific EORTC group, a medical or a methodological research programme in Brussels.
The EORTC invites you to support the manifesto on Treatment Optimisation. Please confirm your support before the 28th Feb. 2019.